2026 / 03

DOI: 10.24075/vrgmu.2026.034
Авторские права: © 2026 принадлежат авторам. Лицензиат: РНИМУ им. Н.И. Пирогова.
Статья размещена в открытом доступе и распространяется на условиях лицензии Creative Commons Attribution (CC BY).

ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ

Лиганд 19 хемокина (мотив C–C) и интерлейкин 23 у пациентов с постлаймским синдромом с поражением нервной системы

Н. С. Баранова , Я. С. Остапенко , А. А. Баранов , Л. А. Овсяникова , Н. Н. Спирин , О. П. Речкина , С. С. Золотавкина , О. В. Вдовенко , Н. В. Семечкин
Информация об авторах

Ярославский государственный медицинский университет, Ярославль, Россия

Для корреспонденции: Наталия Сергеевна Баранова
ул. Революционная, д. 5, г. Ярославль, 150000, Россия; ur.liam@sn_avonarab

Информация о статье

Финансирование: работа выполнена при финансовой поддержке Министерства социальных коммуникаций и научно-технологического развития Ярославской области (соглашение (грант) № 26НП/2024 от 25 декабря 2024 г.).

Вклад авторов: Н. С. Баранова, Я. С. Остапенко, А. А. Баранов, Н. Н. Спирин — планирование и дизайн исследования; Я. С. Остапенко, Л. А. Овсяникова, О. П. Речкина, С. С. Золотавкина, О. В. Вдовенко, Н. В. Семечкин — сбор данных и проведение исследования; Н. С. Баранова, Я. С. Остапенко, А. А. Баранов — анализ данных; Н. С. Баранова, Я. С. Остапенко, А. А. Баранов — написание статьи.

Соблюдение этических стандартов: исследование одобрено этическим комитетом ФГБОУ ВО ЯГМУ Минздрава России (протокол № 63 от 14 сентября 2023 г.). Все пациенты подписали добровольное информированное согласие.

Статья получена: 18.05.2026 Статья принята к печати: 13.06.2026 Опубликовано online: 26.06.2026
|
  1. Клинические рекомендации. Болезнь Лайма у взрослых. 2025. Доступно по ссылке: http://medelement.com/disease/ болезнь-лайма-у-взрослых-кр-рф-2025/19081 (дата обращения: 10.03.2026).
  2. Рудакова С. А., Теслова О. Е., Муталинова Н. Е., Рудаков Н. В., Пеньевская Н. А., Кузьменко Ю. Ф. и др. Эпидемиологическая ситуация по иксодовым клещевым боррелиозам в Российской Федерации в 2010–2024 гг. и прогноз на 2025 г. Проблемы особо опасных инфекций. 2025; 2: 39–46. DOI: 10.21055/0370-1069-2025-2-39-46.
  3. Steere AC, Strle F, Wormser GP. Hu LT, Branda JA, Hovius JW, et al. Lyme borreliosis. Nat Rev Dis Primers. 2016; 2: 16090. DOI: 10.1038/nrdp.2016.90. Erratum in: Nat Rev Dis Primers. 2017; 3: 17062. DOI: 10.1038/nrdp.2017.62.
  4. Radolf JD, Strle K, Lemieux JE, Strle F. Lyme Disease in Humans. Curr Issues Mol Biol. 2021; 42: 333–84. DOI: 10.21775/cimb.042.333.
  5. Schwartz AM, Kugeler KJ, Nelson CA, Marx GE, Hinckley AF. Use of commercial claims data for evaluating trends in Lyme disease diagnoses, United States, 2010–2018. Emer Infect Dis. 2021; 27 (2): 499–507. DOI: 10.3201/eid2702.202728.
  6. Steinbrink A, Brugger K, Margos G, Kraiczy P, Klimpel S. The evolving story of Borrelia burgdorferi sensu lato transmission in Europe. Parasitol. Res. 2022; 121 (3): 781–803. DOI: 10.1007/ s00436-022-07445-3.
  7. Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006; 43: 1089–134. DOI: 10.1086/508667.
  8. Weitzner E, McKenna D, Nowakowski J, Scavarda C, Dornbush R, Bittker S, et al. Long-term assessment of post-treatment symptoms in patients with culture-confirmed early Lyme disease. Clin Infect Dis. 2015; 61: 1800–6. DOI: 10.1093/cid/civ735.
  9. Shor S, Green C, Szantyr B, Phillips S, Liegner K, Burrascano JJ Jr, et al. Chronic Lyme disease: an evidence-based definition by the ILADS working group. Antibiotics (Basel). 2019; 8: 269. DOI: 10.3390/antibiotics8040269.
  10. Zafar K, Azuama OC, Parveen N. Current and emerging approaches for eliminating Borrelia burgdorferi and alleviating persistent Lyme disease symptoms. Front Microbiol. 2024; 15: 1459202. DOI: 10.3389/fmicb.2024.1459202.
  11. Steere AC. Posttreatment Lyme disease syndromes: distinct pathogenesis caused by maladaptive host responses. J Clin Invest. 2020; 130 (5): 2148–51. DOI: 10.1172/JCI138062.
  12. Soloski MJ, Crowder LA, Lahey LJ, Wagner CA, Robinson WH, Aucott JN. Serum inflammatory mediators as markers of human Lyme disease activity. PLoS One. 2014; 9 (4): e93243. DOI: 10.1371/journal.pone.0093243.
  13. Aucott JN, Soloski MJ, Rebman AW, Crowder LA, Lahey LJ, Wagner CA, et al. CCL19 as a chemokine risk factor for posttreatment Lyme disease syndrome: a prospective clinical cohort study. Clin Vaccine Immunol. 2016; 23 (9): 757–66. DOI: 10.1128/CVI.00071-16.
  14. Strle K, Stupica D, Drouin EE, Steere AC, Strle F. Elevated levels of IL-23 in a subset of patients with post-lyme disease symptoms following erythema migrans. Clin Infect Dis. 2014; 58 (3): 372–80. DOI: 10.1093/cid/cit735.
  15. Hernández SA, Ogrinc K, Korva M, Kastrin A, Bogovič P, Rojko T, et al. Associated of persistent symptoms after Lyme Neuroborreliosis and increased levels of interferon-α in blood. Emerg Infect Dis. 2023; 29 (6): 1091–101. DOI: 10.3201/eid2906.221685.
  16. Adkison H, Embers ME. Lyme disease and the pursuit of a clinical cure. Front Med (Lausanne). 2023; 10: 1183344. DOI: 10.3389/fmed.2023.1183344.
  17. Raffetin A, Saunier A, Bouiller K, Caraux-Paz P, Eldin C, Gallien S, at al. Unconventional diagnostic tests for Lyme borreliosis: a systematic review. Clin Microbiol Infect. 2020; 26 (1): 51–59. DOI: 10.1016/j.cmi.2019.06.033.
  18. Баранова Н. С., Остапенко Я. С., Овсянникова Л. А., Спирин Н. Н., Баранов А. А., Быканова М. А. Клинические особенности поражения нервной системы при постлаймском синдроме. Часть 1. РМЖ. 2026; 4: 7–12. DOI: 10.32364/2225-2282-2026-4-2.
  19. Rupprecht TA, Plate A, Adam M, Wick M, Kastenbauer S, Schmidt C, et al. The chemokine CXCL13 is a key regulator of B cell recruitment to the cerebrospinal fluid in acute Lyme neuroborreliosis. J Neuroinflammation. 2009; 6: 42. DOI: 10.1186/1742-2094-6-42.
  20. Girgis AA, Cimbro R, Yang T, Rebman AW, Sewell T, Villegas de Flores D, et al. Aberrant T-cell phenotypes in a cohort of patients with post-treatment Lyme disease. Front Immunol. 2025; 16: 1607619. DOI: 10.3389/fimmu.2025.1607619.
  21. Eckman EA, Pacheco-Quinto J, Herdt AR, Halperin JJ. Neuroimmunomodulators in neuroborreliosis and Lyme encephalopathy. Clin Infect Dis. 2018; 67 (1): 80–88. DOI: 10.1093/cid/ciy019.
  22. Баранова Н. С., Овсянникова Л. А., Остапенко Я. С., Спирин Н. Н, Баранов А. А., Грись М. С. и др. Уровень цитокинов у пациентов с рассеянным склерозом и хроническим нейроборрелиозом. Неврология, нейропсихиатрия, психосоматика. 2024; 16: 57– 64. DOI: 10.14412/2074-2711-2024-2S-57-64.
  23. Uhde M, Ajamian M, Li X, Wormser GP, Marques A, Alaedini A. Expression of C-reactive protein and serum amyloid A in early to late manifestations of Lyme disease. Clin Infect Dis. 2016; 63: 1399–404. DOI: 10.1093/cid/ciw599.
  24. Рудакова С. А., Рудаков Н. В., Штрек С. В., Теслова О. Е., Канешова Н. Е. Геновидовая характеристика клещевых боррелиозов в России. Фундаментальная и клиническая медицина. 2021; 6 (3): 94–99. DOI: 10.23946/2500-0764-2021-6-3-94-99.
  25. Tveita A, Murphy SL, Holter JC, Kildal AB, Michelsen AE, Lerum TV, et al. High circulating levels of the homeostatic chemokines CCL19 and CCL21 predict mortality and disease severity in COVID-19. J Infect Dis. 2022; 226 (12): 2150–60. DOI: 10.1093/infdis/jiac313.
  26. Kalish RA, McHugh G, Granquist J, Shea B, Ruthazer R, Steere AC. Persistence of immunoglobulin M or immunoglobulin G antibody responses to Borrelia burgdorferi 10–20 years after active Lyme disease. Clin Infect Dis. 2001; 33 (6): 780–5. DOI: 10.1086/322669.
  27. Blum LK, Adamska, J Z, Martin DS, Rebman, AW, Elliott SE, Cao RRL, et al. Robust B cell responses predict rapid resolution of Lyme disease. Front. Immunol. 2018; 9: 1634. DOI: 10.3389/fimmu.2018.01634.
  28. Bockenstedt LK, Wooten RM, Baumgarth N. Immune response to Borrelia: lessons from Lyme Disease spirochetes. Curr Issues Mol Biol. 2021; 42: 145–190. DOI: 10.21775/cimb.042.145.
  29. Nakano K, Whitehead GS, Lyons-Cohen MR, Grimm SA, Wilkinson CL, Izumi G, et al. Chemokine CCL19 promotes type 2 T-cell differentiation and allergic airway inflammation. J Allergy Clin Immunol. 2024; 153 (2): 487–502.e9. DOI: 10.1016/j.jaci.2023.10.024.
  30. Yan Y, Chen R, Wang X, Hu K, Huang L, Lu M, et al. CCL19 and CCR7 expression, signaling pathways, and adjuvant functions in viral infection and prevention. Front Cell Dev Biol. 2019; 7: 212. DOI: 10.3389/fcell.2019.00212.
  31. Bielecki B, Jatczak-Pawlik I, Wolinski P, Bednarek A, Glabinski A. Central nervous system and peripheral expression of CCL19, CCL21 and their receptor CCR7 in experimental model of multiple sclerosis. Arch Immunol Ther Exp (Warsz). 2015; 63 (5): 367–76. DOI: 10.1007/s00005-015-0339-9.
  32. Krumbholz M, Theil D, Steinmeyer F, Cepok S, Hemmer B, Hofbauer M, et al. CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions. J Neuroimmunol. 2007; 190 (1–2): 72– 9. DOI: 10.1016/j.jneuroim.2007.07.024.
  33. Hastey CJ, Ochoa J, Olsen KJ, Barthold SW, Baumgarth N. MyD88- and TRIF-independent induction of type I interferon drives naive B cell accumulation but not loss of lymph node architecture in Lyme disease. Infect Immun. 2014; 82: 1548 –8. DOI: 10.1128/IAI .00969-13.
  34. Li Y, Yu X, Ma Y, Hua S. IL-23 and dendritic cells: What are the roles of their mutual attachment in immune response and immunotherapy? Cytokine. 2019; 120: 78–84. DOI: 10.1016/j.cyto.2019.02.018.
  35. Kuwabara T, Tanaka Y, Ishikawa F, Kondo M, Sekiya H, Kakiuchi T. CCR7 ligands up-regulate IL-23 through PI3-kinase and NF-κ B pathway in dendritic cells. J Leukoc Biol. 2012; 92 (2): 309–18. DOI: 10.1189/jlb.0811415.
  36. Gutierrez-Hoffmann M, Fan J, O'Meally RN, Cole RN, Florea L, Antonescu C, et al. The Interaction of Borrelia burgdorferi with Human Dendritic Cells: Functional Implications. J Immunol. 2023; 211 (4): 612–25. DOI: 10.4049/jimmunol.2300235.
  37. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007; 8 (3): 239–45. DOI: 10.1038/ni1443.
  38. Helble JD, McCarthy JE, Sawden M, Starnbach MN, Hu LT. The PD-1/PD-L1 pathway is induced during Borrelia burgdorferi infection and inhibits T cell joint infiltration without compromising bacterial clearance. PLoS Pathog. 2022; 18 (10): e1010903. DOI: 10.1371/journal.ppat.1010903.
  39. Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016; 44 (5): 989–1004. DOI: 10.1016/j.immuni.2016.05.001.
  40. Lochhead RB, Strle K, Arvikar SL, Weis JJ, Steere AC. Lyme arthritis: linking infection, inflammation and autoimmunity. Nat Rev Rheumatol. 2021; 17 (8): 449–61. DOI: 10.1038/s41584-021-00648-5.
  41. Harden JL, Egilmez NK. Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity. Immunol Invest. 2012; 41 (6–7): 738– 64. DOI: 10.3109/08820139.2012.676122.
  42. Thompson D, Sorenson J, Greenmyer J, Brissette CA, Watt JA. The Lyme disease bacterium, Borrelia burgdorferi, stimulates an inflammatory response in human choroid plexus epithelial cells. PLoS One. 2020; 15 (7): e0234993. DOI: 10.1371/journal.pone.0234993.
  43. Barwe SP, Skay A, McSpadden R, Huynh TP, Langhans SA, Inge LJ, et al. Na,K-ATPase β-subunit cis homo-oligomerization is necessary for epithelial lumen formation in mammalian cells. J Cell Sci. 2012; 125 (Pt 23): 5711–20. DOI: 10.1242/jcs.108795.
  44. Laaker C, Baenen C, Kovács KG, Sandor M, Fabry Z. Immune cells as messengers from the CNS to the periphery: the role of the meningeal lymphatic system in immune cell migration from the CNS. Front Immunol. 2023; 14: 1233908. DOI: 10.3389/fimmu.2023.1233908.
  45. Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med. 2012; 4 (147): 147ra111. DOI: 10.1126/scitranslmed.3003748.
  46. Cai Y, Zhang Y, Leng S, Ma Y, Jiang Q, Wen Q, et al. The relationship between inflammation, impaired glymphatic system, and neurodegenerative disorders: A vicious cycle. Neurobiol Dis. 2024; 192: 106426. DOI: 10.1016/j.nbd.2024.106426.
  47. Mader S, Brimberg L. Aquaporin-4 Water Channel in the Brain and Its Implication for Health and Disease. Cells. 2019; 8 (2): 90. DOI: 10.3390/cells8020090.
  48. Morley SC. T cells go with the flow: aquaporin 4 is required for full T-cell activation. J Leukoc Biol. 2023; 113 (6): 541–3. DOI: 10.1093/jleuko/qiad041.
  49. Nicosia M, Lee J, Beavers A, Kish D, Farr GW, McGuirk PR, et al. Water channel aquaporin 4 is required for T cell receptor mediated lymphocyte activation. J Leukoc Biol. 2023; 113 (6): 544–54. DOI: 10.1093/jleuko/qiad010.
  50. Skucas VA, Mathews IB, Yang J, Cheng Q, Treister A, Duffy AM, et al. Impairment of select forms of spatial memory and neurotrophin-dependent synaptic plasticity by deletion of glial aquaporin-4. J Neurosci. 2011; 31: 6392–7. DOI: 10.1523/JNEUROSCI.6249-10.2011.
  51. Zhang J, Li Y, Chen ZG, Dang H, Ding JH, Fan Y, et al. Glia protein aquaporin-4 regulates aversive motivation of spatial memory in Morris water maze. CNS Neurosci Ther. 2013; 19: 937–44. DOI: 10.1111/cns.12191.
  52. Nemat-Gorgani M, Jensen MA, Davis RW. Glymphatic system dysregulation as a key contributor to myalgic encephalomyelitis/ chronic fatigue syndrome. Int J Mol Sci. 2025; 26 (23): 11524. DOI: 10.3390/ijms262311524.
  53. Турпаев К. Т. Транскрипционный фактор KLF2 и его роль в регуляции воспалительных процессов. Обзор. Биохимия, 2020; 85 (1): 64–79 DOI: 10.31857/S0320972520010054.
  54. Xu S, Liu Y, Ding Y, Luo S, Zheng X, Wu X, et al. The zinc finger transcription factor, KLF2, protects against COVID-19 associated endothelial dysfunction. Signal Transduct Target Ther. 2021; 6 (1): 266. DOI: 10.1038/s41392-021-00690-5.
  55. Lei L, Chen M, Wang C, Jiang X, Li Y, Wang W, et al. Trichostatin D as a Novel KLF2 Activator Attenuates TNFα-Induced Endothelial Inflammation. Int J Mol Sci. 2022; 23 (21): 13477. DOI: 10.3390/ijms232113477.
  56. Jha P, Das H. KLF2 in Regulation of NF-κB-Mediated Immune Cell Function and Inflammation. Int J Mol Sci. 2017; 18 (11): 2383. DOI: 10.3390/ijms18112383.
  57. Tsui C, Heyden L, Wen L, Gago da Graça C, Potemkin N, Frolov A, et al. Lymph nodes fuel KLF2-dependent effector CD8+ T cell differentiation during chronic infection and checkpoint blockade. Nat Immunol. 2025; 26 (10): 1752–65. DOI: 10.1038/s41590-025-02276-7.